Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 18/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133707 | 0.91 | HRH3 (0.33) | ADORA2AADORA1 | |
| SCHEMBL6134875 | 0.90 | ADORA2A (0.40) | ADORA2AADORA1 | |
| SCHEMBL6133812 | 0.88 | PTGS2 (0.35) | ADORA2AADORA1 | |
| SCHEMBL6134394 | 0.86 | ADORA2A (0.40) | ADORA2AADORA1 | |
| SCHEMBL6134544 | 0.84 | ADORA2A (0.46) | ADORA2AADORA1TP53 | |
| SCHEMBL6133734 | 0.83 | ADORA2A (0.45) | ADORA2AADORA1TP53 | |
| SCHEMBL6134022 | 0.83 | ADORA2A (0.45) | ADORA2AADORA1TP53 | |
| SCHEMBL6134523 | 0.83 | ADORA2A (0.45) | ADORA2AADORA1TP53 | |
| SCHEMBL5151056 | 0.82 | TP53 (0.34) | ADORA2AADORA1TP53 | |
| SCHEMBL6133453 | 0.81 | ADORA2A (0.42) | ADORA2AADORA1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885TP53 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.